S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed solid tumor or lymphoma for which standard curative or palliative measures do not exist or are no longer effective
• * Pathological confirmation of diagnosis not required in patients with liver mass, raised alpha-fetoprotein levels (at least 500 ng/mL), and positive serology for hepatitis consistent with a diagnosis of hepatocellular carcinoma
• * Any solid tumor or lymphoma tumor type eligible
• * Must have had thoracic and upper abdominal CT scan, including entire liver and adrenals, within 28 days before study entry
• Patients with glioma or brain metastases must be on a stable dose of corticosteroids and be seizure-free for the past month
• * Prior whole brain or gamma knife radiotherapy required for known brain metastases
• * No unstable or untreated (non-irradiated) brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Zubrod 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• No active hemolysis
• Hepatic
• See Disease Characteristics
• Patients with biliary obstruction for which a shunt has been placed are allowed if shunt is in place for at least 10 days and liver function is stable
• Abnormal liver function (bilirubin and SGOT) allowed regardless of cause (metastases or other causes)
• No evidence of biliary sepsis
• Renal
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• No concurrent uncontrolled illness
• No ongoing or active infection
• No uncontrolled diarrhea
• No peripheral neuropathy grade II or greater
• No psychiatric illness or social situation that would preclude study compliance
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy for malignancy
• Chemotherapy
• More than 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy for malignancy
• Endocrine therapy
• See Disease Characteristics
• No concurrent oral contraceptives
• No concurrent hormone therapy for malignancy
• * Concurrent luteinizing hormone-releasing hormone agonists allowed
• Radiotherapy
• See Disease Characteristics
• More than 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy for malignancy
• Surgery
• More than 2 weeks since prior major surgery
• Other
• Recovered from prior therapy
• No concurrent medications that are known to be inhibitors of CYP3A4